Search

Displaying results 4961 - 4970 of 7283 in total
  1. Drug

    Invert sugar

    go.drugbank.com/drugs/DB09344
    Experimental

    [A32124] Invert sugar is FDA approved since 1988 as a safe substance (GRAS).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Indotecan

    go.drugbank.com/drugs/DB18752
    Investigational

    Categories: DNA Topoisomerases, Type I
  3. Drug

    Prostaglandin D2

    go.drugbank.com/drugs/DB02056
    Experimental

    The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, ...

    Categories: Prostaglandins D, Prostaglandin D2, antagonists & inhibitorsSynonyms: Prostaglandin D2
  4. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian. … Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form.

  5. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. … As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.

  6. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. … The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA.

  7. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. … H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].

  8. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    a short peptide linker. … [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]

  9. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.

  10. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. … [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate.